Holen Sie sich die Stockscreener-App
6.33
13.73%
0.76
Schlusskurs vom Vortag:
$5.57
Offen:
$6.07
24-Stunden-Volumen:
1.09M
Relative Volume:
1.89
Marktkapitalisierung:
$205.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.25M
KGV:
-5.3373
EPS:
-1.186
Netto-Cashflow:
$-22.80M
1W Leistung:
+5.76%
1M Leistung:
+0.88%
6M Leistung:
-33.32%
1J Leistung:
+17.97%
1-Tages-Spanne:
$5.95
$6.63
1-Wochen-Bereich:
$5.43
$6.63
52-Wochen-Spanne:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Firmenname
Sagimet Biosciences Inc
Sektor
Branche
Telefon
(650) 561-8600
Adresse
155 BOVET RD., SUITE 303, SAN MATEO
Vergleichen Sie SGMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
6.325 | 181.15M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.17 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.36 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.32 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Eingeleitet | Wedbush | Outperform |
| 2025-08-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-24 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-12-06 | Eingeleitet | Oppenheimer | Outperform |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Herabstufung | Goldman | Buy → Neutral |
| 2024-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-25 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-08 | Eingeleitet | Goldman | Buy |
| 2023-08-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-08 | Eingeleitet | Piper Sandler | Overweight |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Why Sagimet Biosciences Inc. stock remains on watchlistsJuly 2025 Recap & AI Powered Market Entry Strategies - ulpravda.ru
Why retail investors favor Sagimet Biosciences Inc. stockQuarterly Investment Review & AI Based Buy and Sell Signals - ulpravda.ru
Why Sagimet Biosciences Inc. stock could be next big winnerRisk Management & Reliable Breakout Forecasts - ulpravda.ru
Can Sagimet Biosciences Inc. stock beat market expectations this quarterJuly 2025 PreEarnings & AI Driven Price Forecasts - ulpravda.ru
How Sagimet Biosciences Inc. stock performs in stagflationJuly 2025 News Drivers & Stepwise Trade Execution Plans - ulpravda.ru
Published on: 2026-01-08 19:16:00 - ulpravda.ru
Study links experimental drug to improved liver fibrosis in MASH patients - Stock Titan
Falcon Technoprojects India Limited Chart Enters High Volatility ZoneTake Profit Strategies & Fast Growing Trading Ideas - earlytimes.in
Sagimet Biosciences Inc. (SGMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely - Yahoo Finance
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Disc Medicine (IRON) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $26 - 富途牛牛
Sagimet rises as licensing deal with Teva unit targets Madrigal drug - MSN
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts - TipRanks
Why Sagimet Biosciences Inc. stock could rally in 2025Gap Up & Verified Entry Point Detection - Улправда
Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 5.4%Still a Buy? - MarketBeat
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT) - Seeking Alpha
Can Sagimet Biosciences Inc. stock maintain growth trajectoryJuly 2025 Levels & Daily Entry Point Trade Alerts - DonanımHaber
Sagimet reports positive Phase 1 results for MASH combination therapy By Investing.com - Investing.com Australia
How Sagimet Biosciences Inc. stock performs in high volatility marketsPrice Action & Low Volatility Stock Suggestions - DonanımHaber
Guidance Update: Why Sagimet Biosciences Inc. stock could be next big winner - Улправда
How Sagimet Biosciences Inc. (0O2) stock compares with top peersWeekly Investment Summary & Daily Chart Pattern Signals - Улправда
Investment Review: Why Sagimet Biosciences Inc. stock could be next big winnerMarket Sentiment Review & Fast Exit and Entry Trade Guides - Улправда
Sagimet Highlights Positive MASH Combo Data and Pipeline Progress - TipRanks
Sagimet reports positive Phase 1 results for MASH combination therapy - Investing.com India
Sagimet Biosciences Announces Positive Phase 1 PK Trial Results - TradingView — Track All Markets
[8-K] Sagimet Biosciences Inc. Reports Material Event | SGMT SEC FilingForm 8-K - Stock Titan
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination - The Manila Times
Sagimet Biosciences Announces Positive Results from the - GlobeNewswire
Sagimet Biosciences (Nasdaq:SGMT) Secures Global License for Resmetirom API in Combination Program - Kalkine Media
Sagimet Biosciences enters global license agreement with TAPI - MSN
Strategic Licensing and Pipeline Advancements Drive Buy Rating for Sagimet Biosciences - TipRanks
Sagimet Biosciences Signs License Agreement With Teva Subsidiary for Resmetirom Development - marketscreener.com
TEVA's Subsidiary Grants License to Sagimet for Innovative Drug Development - GuruFocus
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program - The Manila Times
Sagimet Biosciences Inc Enters License Agreement with TAPI - TradingView — Track All Markets
Sagimet Biosciences (NASDAQ: SGMT) signs TAPI deal for resmetirom API combo - Stock Titan
Sagimet Biosciences and TAPI Announce Global License - GlobeNewswire
Sagimet Biosciences Earnings Notes - Trefis
What the Technical Setup Suggests for HCKK Ventures Limited in the Next 30 Days - earlytimes.in
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio - Barchart.com
Sagimet Biosciences announces China’s NMPA accepted NDA for denifanstat - MSN
Sagimet's license partner Ascletis announced acceptance of new drug application for Denifanstat - marketscreener.com
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration - The Manila Times
Sagimet Biosciences Licenses Denifanstat for Acne Treatment to Ascletis Pharma as NMPA Accepts NDA in China - Quiver Quantitative
Sagimet Biosciences (Nasdaq: SGMT) sees China partner’s acne drug NDA accepted by NMPA - Stock Titan
SGMTSagimet Biosciences Inc. Latest Stock News & Market Updates - Stock Titan
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Finanzdaten der Sagimet Biosciences Inc-Aktie (SGMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):